<- Go Home
Sio Gene Therapies Inc.
Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.
Market Cap
$35.4M
Volume
565.5K
Cash and Equivalents
$46.1M
EBITDA
-$27.2M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$0.50
52 Week Low
$0.25
Dividend
N/A
Price / Book Value
0.78
Price / Earnings
-1.22
Price / Tangible Book Value
0.78
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
-$27.4M
Return on Equity
47.50%
Return on Assets
-24.34
Cash and Short Term Investments
$46.1M
Debt
N/A
Equity
$45.1M
Revenue
N/A
Unlevered FCF
-$24.7M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium